Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination.

Parker WT, Phillis SR, Yeung DT, Hughes TP, Scott HS, Branford S.

Blood. 2014 Jul 3;124(1):153-5. doi: 10.1182/blood-2014-05-573485. No abstract available.

2.

Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR.

Pelz-Ackermann O, Cross M, Pfeifer H, Deininger M, Wang SY, Al-Ali HK, Niederwieser D, Lange T.

Leukemia. 2008 Dec;22(12):2288-91. doi: 10.1038/leu.2008.180. Epub 2008 Jul 10. No abstract available.

PMID:
18615107
3.

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.

Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, Müller MC, Radich JP, Shah NP.

Leuk Res. 2014 Jan;38(1):10-20. doi: 10.1016/j.leukres.2013.09.011. Epub 2013 Sep 23. Review.

4.

Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.

Moore FR, Yang F, Press RD.

Methods Mol Biol. 2013;999:25-39. doi: 10.1007/978-1-62703-357-2_2.

PMID:
23666688
5.

Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.

Shih LY, Kuo MC, Kuo CY, Lin TH, Bai LY, Chen TY, Wang MC, Lin TL, Lan YJ, Chen CC, Yang Y, Hsiao PC, Lai CL, Chang CH, Lin TH.

Leuk Res. 2013 Jan;37(1):43-9. doi: 10.1016/j.leukres.2012.09.012. Epub 2012 Oct 9.

PMID:
23062378
6.

Identification of e19a2 BCR-ABL fusions (mu-BCR breakpoints) at the DNA level by ligation-mediated PCR.

Boeckx N, Jansen MW, Haskovec C, Vandenberghe P, van der Velden VH, van Dongen JJ.

Leukemia. 2005 Jul;19(7):1292-5. No abstract available.

PMID:
15843824
7.

Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR.

Oehler VG, Qin J, Ramakrishnan R, Facer G, Ananthnarayan S, Cummings C, Deininger M, Shah N, McCormick F, Willis S, Daridon A, Unger M, Radich JP.

Leukemia. 2009 Feb;23(2):396-9. doi: 10.1038/leu.2008.183. Epub 2008 Jul 10. No abstract available.

8.

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, Slader C, Field C, Dang P, Filshie RJ, Mills AK, Grigg AP, Melo JV, Hughes TP.

Leukemia. 2010 Oct;24(10):1719-24. doi: 10.1038/leu.2010.185. Epub 2010 Sep 2.

PMID:
20811403
9.

BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.

Elias MH, Baba AA, Azlan H, Rosline H, Sim GA, Padmini M, Fadilah SA, Ankathil R.

Leuk Res. 2014 Apr;38(4):454-9. doi: 10.1016/j.leukres.2013.12.025. Epub 2014 Jan 6.

PMID:
24456693
10.

Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia.

Moore FR, Rempfer CB, Press RD.

Methods Mol Biol. 2013;999:1-23. doi: 10.1007/978-1-62703-357-2_1.

PMID:
23666687
11.

Detection of BCR-ABL mutations and resistance to imatinib mesylate.

Branford S, Hughes T.

Methods Mol Med. 2006;125:93-106.

PMID:
16502579
12.

A nested RT-PCR assay to detect BCR/abl.

Wasserman LM.

Methods Mol Med. 2004;97:181-9. No abstract available.

PMID:
15064493
14.

BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay.

Ono T, Miyawaki S, Kimura F, Kanamori H, Ohtake S, Kitamura K, Fujita H, Sugiura I, Usuki K, Emi N, Tamaki S, Aoyama Y, Kaya H, Naoe T, Tadokoro K, Yamaguchi T, Ohno R, Ohnishi K; Japan Adult Leukemia Study Group.

Leuk Res. 2011 May;35(5):598-603. doi: 10.1016/j.leukres.2010.12.006. Epub 2011 Jan 15.

PMID:
21239056
15.

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.

Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF, Durrant S, Browett P, Schwarer AP, Arthur C, Catalano J, Leahy MF, Filshie R, Bradstock K, Herrmann R, Joske D, Lynch K, Hughes T.

Blood. 2004 Nov 1;104(9):2926-32. Epub 2004 Jul 15.

16.

Early detection and quantification of mutations in the tyrosine kinase domain of chimerical BCR-ABL1 gene combining high-resolution melting analysis and mutant-allele specific quantitative polymerase chain reaction.

Ferri C, Bianchini M, Icardi G, Belli C, Bengió R, Larripa I.

Leuk Lymphoma. 2013 Mar;54(3):598-606. doi: 10.3109/10428194.2012.718767. Epub 2012 Aug 31.

PMID:
22870928
17.

Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.

Slupianek A, Dasgupta Y, Ren SY, Gurdek E, Donlin M, Nieborowska-Skorska M, Fleury F, Skorski T.

Blood. 2011 Jul 28;118(4):1062-8. doi: 10.1182/blood-2010-09-307256. Epub 2011 Jun 7.

18.

Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia.

Preuner S, Mitterbauer G, Mannhalter C, Herndlhofer S, Sperr WR, Valent P, Lion T.

Eur J Cancer. 2012 Jan;48(2):233-6. doi: 10.1016/j.ejca.2011.08.015. Epub 2011 Sep 28.

PMID:
21955823
19.

Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34 + cells of patients with de novo chronic myeloid leukemia.

Jurcek T, Razga F, Mazancova P, Musilova M, Dvorakova D, Borsky M, Zackova D, Dobesova B, Semerad L, Mayer J, Racil Z.

Leuk Lymphoma. 2014 Aug;55(8):1915-7. doi: 10.3109/10428194.2013.842988. Epub 2014 Feb 6. No abstract available.

PMID:
24304421

Supplemental Content

Support Center